Skip to main content
Equibles
ACXP logo

ACXP · Acurx Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio

Track ACXP — free

Use ACXP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACXP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.34 +0.07 (+5.54%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”
View the 10-Q filed Aug 13, 2026
Market Cap
$7.09M
Shares
5.27M
Volume · Oct 5 82.38K Avg daily vol (3M) 128.45K

Acurx Pharmaceuticals, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Acurx Pharmaceuticals, Inc. (ACXP), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Annual General Meeting
Investor event
2026-10-16
Acurx Pharmaceuticals, Inc. (ACXP) October 2026 Annual General Meeting
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-14
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call
Diluted EPS
$-0.53
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript
Confident tone ibezapolstat (IBZ) clinical program and efficacy Microbiome and recurrence mechanism Phase III and FDA pathway strategy
Diluted EPS
$-0.62
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q3
2025-09-30
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript
Positive tone Microbiome-Sparing Mechanism / Class Effect Ibezapolstat Phase 3 Funding and Strategy Regulatory Designations and FDA Interactions
Diluted EPS
$-1.23
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript
Positive tone Ibezapolstat Phase IIb data and Phase III readiness Financing and capital raising Partnerships and government funding
Diluted EPS
$-1.89
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript
Positive tone Microbiome Differentiation and Publications Ibezapolstat Phase 3 Program and Funding Lancet Microbe Publication
Diluted EPS
$-2.15
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript
Positive tone Ibezapolstat (IBZ) Phase 3 readiness Clinical data and scientific publications Financing and capital raises
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript
Confident tone Ibezapolstat Phase III readiness C. difficile clinical results and anti-recurrence data Intellectual property and patents
Diluted EPS
$-3.45
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-09
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript
Confident tone Ibezapolstat Phase 3 readiness and clinical progress Intellectual property and microbiome patent Financial position and cash runway
Diluted EPS
$-5.21
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-15
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript
Confident tone Phase 3 readiness and FDA alignment Ibezapolstat clinical and microbiology data Phase 3 cost and funding
Diluted EPS
$-5.60
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-18
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcript
Confident tone Phase III Clinical Trial Planning Ibezapolstat Phase IIb Clinical Data FDA Regulatory Pathway
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2023 Earnings Call Transcript
Diluted EPS
$-4.80
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2023 Earnings Call Transcript
Diluted EPS
$-5.60
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2023 Earnings Call Transcript
Diluted EPS
$-5.00
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2022 Earnings Call Transcript
Diluted EPS
$-6.40
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2022 Earnings Call Transcript
Diluted EPS
$-5.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2022 Earnings Call Transcript
Diluted EPS
$-5.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-17
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-16
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2021 Earnings Call Transcript
Diluted EPS
$-9.20
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-16
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2021 Earnings Call
Diluted EPS
$-11.40
Audio Transcript Slides 8-K10-Q
Showing 1–21 of 21 webcasts
Key facts CIK 1736243 CUSIP 00510M203 Visit website Investor relations